Molecular Formula | C18H18N8O7S3 |
Molar Mass | 554.58 |
Density | 1.96±0.1 g/cm3(Predicted) |
Melting Point | 155 °C |
Solubility | DMSO (Slightly), Methanol (Slightly) |
Appearance | Solid |
Color | Off-White to Pale Yellow |
pKa | pKa –3.2±0.6 (Uncertain);–1.8±0.2 (Uncertain);2.57±0.50 (Uncertain);2.90±0.50 (Uncertain);8.03±0.40 |
Storage Condition | 2-8°C(protect from light) |
Refractive Index | 1.889 |
Hazard Symbols | Xn - Harmful |
Risk Codes | 42/43 - May cause sensitization by inhalation and skin contact. |
Safety Description | S22 - Do not breathe dust. S24 - Avoid contact with skin. S37 - Wear suitable gloves. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) |
HS Code | 29349990 |
Reference Show more | 1. Li, Chongyang, et al. "Application of Pretreatments in Prediction Models of Raman Spectra." 2013 5th International Conference on Intelligent Human-Machine Systems and Cybernetics. Vol. 2. IEEE, 2013.https://doi.org/10.1109/IHMSC.2013.262 2. [IF=6.331] Wei Guo et al."Cationic amphiphilic dendrons with effective antibacterial performance."J Mater Chem B. 2021 Dec;: |
Ceftriaxone sodium (Ceftriaxone disodiumstit hemiheptahytate): that is, three-fold hemihydrate of its disodium salt. White or off-white crystalline powder, odorless. Hygroscopicity. mp>155 °c (decomposition). Soluble in water (about 40g/lOOmL, 25 C), slightly soluble in methanol, insoluble in ethanol. Melting point> 155 °c (decomposition).
ceftriaxone sodium: calculated as dry matter. Ceftriaxone (Cis H18 N8 07 S3) shall not be less than 84.0%; The clarity and color of the solution shall be in accordance with the regulations; PH value, pH value shall be 6.0 ~ 8.o (Img the product is soluble in lOmL water); the water content should be 8.o% ~ 11.0%; Impurity content should not be greater than 2.0%; Ceftriaxone polymer by ceftriaxone should not pass 0. 5%; Containing heavy metals should not exceed 0.002%; Abnormal toxicity should be in accordance with the provisions, each 1 mg of ceftriaxone containing toxic amount should be less than 0. 20EU; Sterility should be met.
Roche, Switzerland, was developed in 1978. This product is the third generation cephalosporin antibiotics. Strong activity against Enterobacteriaceae bacteria. Long-acting third-generation cephalosporins, antibacterial spectrum, gram-positive bacteria and negative bacteria have the role; Antibacterial activity, α-lactamase stable, long half-life in serum. For a variety of infections caused by sensitive bacteria, such as sepsis, meningitis, tonsillitis, acute and chronic bronchitis, bronchiectasis, Pneumonia, lung suppuration, ear nose and throat infections, bone and joint infections, chronic respiratory disease secondary infection, peritonitis, cholecystitis, genital infection, etc. Side effects are relatively mild, with long-term, efficient, safe and other characteristics.
male and female mice, male and female rats were intravenously injected with LDso (mg/kg): 3000,2800, 2175,2175; All> 10000 by mouth; All> 5000 by subcutaneous injection.
using 7-ACA (7-aminocephalosporanic acid) as raw material, 7-ACT was synthesized by cyclocondensation with triazine, followed by active ester of amidoxime (phosphorus-containing active ester or mercapto heterocyclic active ester). The condensation forms the cephalosporins. When using the phosphorus-containing active ester, the carboxyl group and hydroxyl group on the 7-ACT must be protected by a silylating reagent such as mono-trimethylacetamide or BIS-methylsilylurea, and its condensation product is ceftriaxone acid, ceftriaxone disodium salt can only be formed by salt formation reaction. When the mercapto heterocyclic active ester is used, the carboxyl group does not need to be protected in advance, and the condensation product forms a salt in one step, so the industry is simpler.